Entry Detail


General Information

Database ID:exR0269356
RNA Name:hsa-miR-1295b-5p
RNA Type:miRNA
Chromosome:chr1
Starnd:+
Coordinate:
Start Site(bp):171101739End Site(bp):171101759
External Links:hsa-miR-1295b-5p



Disease Information

Disease Name:Multiple Sclerosis
Disease Category:Nervous System Diseases
MeSH ID:D009103
Type:Diseases Category/Nervous System Diseases
Alias:Sclerosis, Multiple//Sclerosis, Disseminated//Disseminated Sclerosis//MS (Multiple Sclerosis)//Multiple Sclerosis, Acute Fulminating



Expression Detail

GEO ID:GSE140106
Description:Serum exosome microRNAs predict multiple sclerosis disease activity after fingolimod treatment
Experimental Design:Fingolimod treatment
Case Disease Type:Multiple Sclerosis
Case Disease SubType:NA
Case Sample:Fingolimod treated Multiple Sclerosis
Control Sample:Untreated
Number of Case:27
Number of Control:27
Number of Samples:54





Regulatory Relationship

mRNA targets:NA
miRNA targets:NA
circRNA targets:NA
lncRNA targets:NA
Display:N/A



Experiment Detail

GEO ID:GSE140106
Sample Source:Blood
Source Fraction:Exosome
Platform:GPL11154
Method:NGS
Num of detected RNA Type:1
Num of detected RNAs of this Type:1907
Sample treatment protocol:Exosomes were isolated from 1 mL RNase A (37 °C for 10 min; 100 ng/ml; Qiagen, Australia) treated serum, by size exclusion chromatography (qEV iZONE Science).
RNA Extract protocol:Serum exosomes were processed for RNA extraction using the Plasma/Serum Circulating & Exosomal RNA Purification Mini Kit (Norgen Biotek, Cat. 51000) according to the manufacturer's protocol.
RNA library preparation protocol:Exosome RNA sequencing libraries were then constructed using the NEBNext Multiplex Small RNA Library Prep Kit for Illumina (BioLabs, New England) according to the manufacturer's instructions.



Reference

PMID:31721043
Title:Serum Exosome MicroRNAs Predict Multiple Sclerosis Disease Activity after Fingolimod Treatment
Author:Ebrahimkhani S, Beadnall HN, Wang C, Suter CM, Barnett MH, Buckland ME, Vafaee F
Journal:Mol Neurobiol. 2020 Feb;57(2):1245-1258.
Description:we sought the possible utility of serum exosome microRNAs as biomarkers for disease activity in multiple sclerosis patients in response to fingolimod therapy.